Unspecified Adult Solid Tumor, Protocol Specific
759
6
9
607
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
79 trials with published results (10%)
Research Maturity
607 completed trials (80% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
9.9%
75 terminated out of 759 trials
89.0%
+2.5% vs benchmark
9%
67 trials in Phase 3/4
13%
79 of 607 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 607 completed trials
Clinical Trials (759)
Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis
Assessment Tool for Older Patients With Cancer
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction
Registry of Older Patients With Cancer
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing Radiotherapy
Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors